- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04386746
Intravesical Gemcitabine and Docetaxel for BCG naïve Non-muscle Invasive Bladder Cancer (GEMDOCE)
A Phase II Trial for the Use of Intravesical Gemcitabine and Docetaxel (GEMDOCE) in the Treatment of BCG naïve Non-muscle Invasive Urothelial Carcinoma of the Bladder
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- Johns Hopkins University: Sidney Kimmel Comprehensive Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Histologically confirmed intermediate or high-risk non-muscle invasive urothelial carcinoma of the bladder (Ta, T1, or Tis stage) on TURBT obtained within 90 days of registration defined according to modified EORTC risk criteria summarized as follows:
Low-risk tumors: Initial or recurrent tumor > 12 months after resection with all of the following:
- Solitary tumor
- Low-grade
- < 3 cm
- No carcinoma in situ (CIS)
- Intermediate-risk tumors: All tumors not defined in the two adjacent categories (between the category of low- and high-risk)
High-risk tumors: Any of the following:
- T1 tumor
- High-grade
- CIS
- Multiple and recurrent and large (> 3 cm) Ta low-grade tumors (all conditions must be met for this point of Ta low-grade tumors)
- Note #1: Low-risk tumors as defined above are not eligible
- Note #2: Mixed histologies are permitted, provided a component of urothelial carcinoma is present
- Note #3: All patients with high-grade T1 (HGT1) should undergo a restaging TURBT
- Eastern Cooperative Oncology Group (ECOG) (WHO) performance status 0, 1, or 2
- Age ≥ 18 years old at time of consent
Evidence of post-menopausal status or negative urinary or serum pregnancy test or female pre-menopausal patients is required. Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply:
- Women <50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution or underwent surgical sterilization (bilateral oophorectomy or hysterectomy).
- Women ≥50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses >1 year ago, had chemotherapy-induced menopause with last menses >1 year ago, or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy or hysterectomy).
- Subjects who give a written informed consent obtained according to local guidelines.
Exclusion Criteria:
Subjects with muscle-invasive (i.e. T2, T3, T4), locally advanced unresectable, or metastatic urothelial carcinoma as assessed on baseline radiographic imaging obtained within 90 days prior to study registration. The required radiographic imaging includes:
- Abdomen/Pelvis - CT scan
- Chest - chest x-ray or CT scan
Subjects with concurrent upper urinary tract (i.e. ureter, renal pelvis) urothelial carcinoma of any stage.
a. Note: Subjects with history of non-invasive (Ta, Tis) upper tract urothelial carcinoma that has been definitively treated with at least one post-treatment disease assessment (i.e. cytology, biopsy, imaging) that demonstrates no evidence of residual disease are eligible.
- Subjects with another active second malignancy with an estimated overall survival from the second malignancy of < 12 months. Subjects with another second active malignancy that are deemed to have an estimated overall survival of >12 months are eligible.
- Subjects who have received the last administration of an anti-cancer therapy including chemotherapy, immunotherapy, and monoclonal antibodies ≤ 4 weeks prior to starting study drug, or who have not recovered from the side effects of such therapy.
- Subjects who have had radiotherapy ≤ 4 weeks prior to starting study drug, or who have not recovered from radiotherapy toxicities.
- Pregnant or breast-feeding women.
- Subjects unwilling or unable to comply with the protocol.
- Patients with prior systemic gemcitabine or docetaxel use for a non-bladder malignancy may enroll and receive treatment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intravesical Gemcitabine/Docetaxel
Gemcitabine/Docetaxel induction is given intravesically in sequential order once a week for six consecutive weeks.
One gram of gemcitabine in 50 ml of sterile water is slowly instilled into the bladder via a Foley catheter and the catheter is clamped for 60 minutes.
The bladder is then drained and 40 mg of docetaxel in 50 ml of NSS is then slowly instilled via the Foley catheter into the bladder.
The catheter is again clamped for 60 minutes before draining.
If initial efficacy seen, patients will have monthly maintenance instillations of Gemcitabine/Docetaxel.
|
1g gemcitabine in 50ml sterile water; instilled once weekly for 6 weeks and then once monthly for ≤ 21 months.
Other Names:
37.5mg docetaxel in 50ml normal saline solution (NSS); instilled once weekly for 6 weeks and then once monthly for ≤ 21 months.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
3-Month Complete Response Rate
Time Frame: 3 months
|
Number of patients with no evidence of recurrent high grade urothelial carcinoma of the bladder of any stage as assessed by cystoscopy with biopsy and urine cytology.
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
12-Month Relapse-Free Survival Rate
Time Frame: 12 months
|
Proportion of patients alive and with no evidence of recurrent high grade urothelial carcinoma of the bladder of any stage.
|
12 months
|
24-Month Relapse-Free Survival Rate
Time Frame: 24 months
|
Proportion of patients alive and with no evidence of recurrent high grade urothelial carcinoma of the bladder of any stage.
|
24 months
|
Safety Profile as Assessed by Proportion of Adverse Events by Type
Time Frame: Up to 24 months
|
Proportion of adverse events by type, as defined by Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5.0).
|
Up to 24 months
|
Safety Profile as Assessed by Proportion of Adverse Events by Grade
Time Frame: Up to 24 months
|
Proportion of adverse events by grade, as defined by Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5.0).
|
Up to 24 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Gene Alterations as Measured by RNA-seq
Time Frame: 3 months
|
Number of gene alterations as measured by RNA-seq.
Compare results to 3-month Complete Response rate using statistical methods.
|
3 months
|
Type of Gene Alterations as Measured by RNA-seq
Time Frame: 3 months
|
Type of gene alterations as measured by RNA-seq.
Compare results to 3-month Complete Response rate using statistical methods.
|
3 months
|
Number of Gene Alterations as Measured by RNA-seq
Time Frame: 12 months
|
Number of gene alterations as measured by RNA-seq.
Compare results to 12-month Relapse-Free Survival rate using statistical methods.
|
12 months
|
Type of Gene Alterations as Measured by RNA-seq
Time Frame: 12 months
|
Type of gene alterations as measured by RNA-seq.
Compare results to 12-month Relapse-Free Survival rate using statistical methods.
|
12 months
|
Number of DNA Mutations as Measured by Whole Transcriptome
Time Frame: 3 months
|
Number of DNA mutations as measured by whole transcriptome.
Compare results to 3-month Complete Response rate.
|
3 months
|
Number of DNA Mutations as Measured by Whole Exome
Time Frame: 3 months
|
Number of DNA mutations as measured by whole exome.
Compare results to 3-month Complete Response rate.
|
3 months
|
Number of DNA Mutations as Measured by Panel DNA Sequencing
Time Frame: 3 months
|
Number of DNA mutations as measured by panel DNA sequencing.
Compare results to 3-month Complete Response rate.
|
3 months
|
Type of DNA Mutations as Measured by Whole Transcriptome
Time Frame: 3 months
|
Type of DNA mutations as measured by whole transcriptome.
Compare results to 3-month Complete Response rate.
|
3 months
|
Type of DNA Mutations as Measured by Whole Exome
Time Frame: 3 months
|
Type of DNA mutations as measured by whole exome.
Compare results to 3-month Complete Response rate.
|
3 months
|
Type of DNA Mutations as Measured by Panel DNA Sequencing
Time Frame: 3 months
|
Type of DNA mutations as measured by panel DNA sequencing.
Compare results to 3-month Complete Response rate.
|
3 months
|
Number of DNA Mutations as Measured by Whole Transcriptome
Time Frame: 12 months
|
Number of DNA mutations as measured by whole transcriptome.
Compare results to 12-month Relapse Free Survival rate using statistical analysis.
|
12 months
|
Number of DNA Mutations as Measured by Whole Exome
Time Frame: 12 months
|
Number of DNA mutations as measured by whole exome.
Compare results to 12-month Relapse Free Survival rate using statistical analysis.
|
12 months
|
Number of DNA Mutations as Measured by Panel DNA Sequencing
Time Frame: 12 months
|
Number of DNA mutations as measured by panel DNA sequencing.
Compare results to 12-month Relapse Free Survival rate using statistical analysis.
|
12 months
|
Type of DNA Mutations as Measured by Whole Transcriptome
Time Frame: 12 months
|
Type of DNA mutations as measured by whole transcriptome.
Compare results to 12-month Relapse Free Survival rate using statistical analysis.
|
12 months
|
Type of DNA Mutations as Measured by Whole Exome
Time Frame: 12 months
|
Type of DNA mutations as measured by whole exome.
Compare results to 12-month Relapse Free Survival rate using statistical analysis.
|
12 months
|
Type of DNA Mutations as Measured by Panel DNA Sequencing
Time Frame: 12 months
|
Type of DNA mutations as measured by panel DNA sequencing.
Compare results to 12-month Relapse Free Survival rate using statistical analysis.
|
12 months
|
Numbers of T-cell Subpopulations
Time Frame: 3 months
|
Numbers of t-cell subpopulations utilizing immunohistochemical (IHC) staining and flow cytometry.
Compare results to 3-month Complete Response rate using statistical analysis.
|
3 months
|
Ratio of T-cell Subpopulations
Time Frame: 3 months
|
Ratio of t-cell subpopulations utilizing IHC staining and flow cytometry.
Compare results to 3-month Complete Response rate using statistical analysis.
|
3 months
|
Numbers of T-cell Subpopulations
Time Frame: 12-months
|
Numbers of t-cell subpopulations utilizing IHC staining and flow cytometry.
Compare results to 12-month Relapse-Free Survival rate using statistical analysis.
|
12-months
|
Ratio of T-cell Subpopulations
Time Frame: 12-months
|
Ratio of t-cell subpopulations utilizing IHC staining and flow cytometry.
Compare results to 12-month Relapse-Free Survival rate using statistical analysis.
|
12-months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Max Kates, MD, Johns Hopkins University
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Urologic Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Urologic Diseases
- Neoplasms, Glandular and Epithelial
- Urinary Bladder Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Carcinoma
- Urinary Bladder Neoplasms
- Carcinoma, Transitional Cell
- Molecular Mechanisms of Pharmacological Action
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Docetaxel
- Gemcitabine
Other Study ID Numbers
- J2020
- IRB00241941 (Other Identifier: Johns Hopkins Institutional Review Boards)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bladder Cancer
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedStage III Bladder Cancer | No Evidence of Disease | Stage II Bladder Cancer | Stage IVA Bladder Cancer | Stage IVB Bladder CancerUnited States
-
H. Lee Moffitt Cancer Center and Research InstituteCompletedMuscle-Invasive Bladder Carcinoma | Bladder Cancer Stage II | Bladder Cancer Stage III | Bladder Cancer Stage IVUnited States
-
National Cancer Institute (NCI)CompletedStage III Bladder Cancer | Stage I Bladder Cancer | Stage II Bladder CancerUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)WithdrawnRecurrent Bladder Cancer | Urinary Complications | Stage 0 Bladder Cancer | Stage I Bladder Cancer | Stage II Bladder Cancer
-
National Cancer Institute (NCI)TerminatedStage III Bladder Cancer | Stage IV Bladder Cancer | Recurrent Bladder Carcinoma | Bladder Adenocarcinoma | Bladder Squamous Cell Carcinoma | Bladder Urothelial Carcinoma | Stage I Bladder Cancer | Stage II Bladder CancerUnited States
-
Fox Chase Cancer CenterTerminatedStage III Bladder Cancer | Distal Urethral Cancer | Proximal Urethral Cancer | Squamous Cell Carcinoma of the Bladder | Urethral Cancer Associated With Invasive Bladder Cancer | Stage II Bladder CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedStage III Bladder Cancer | Stage IV Bladder Cancer | Recurrent Bladder Carcinoma | Stage II Bladder CancerUnited States
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Bristol-Myers SquibbRecruitingUrinary Bladder Cancer | Invasive Bladder CancerNetherlands
-
Baylor College of MedicinePfizerTerminatedBladder Cancer | Invasive Bladder Cancer | Metastatic Bladder CancerUnited States
-
Taris Biomedical LLCBristol-Myers SquibbTerminatedBladder Cancer TNM Staging Primary Tumor (T) T2 | Bladder Cancer TNM Staging Primary Tumor (T) T2A | Bladder Cancer TNM Staging Primary Tumor (T) T2B | Bladder Cancer TNM Staging Primary Tumor (T) T3 | Bladder Cancer TNM Staging Primary Tumor (T) T3A | Bladder Cancer TNM Staging Primary Tumor... and other conditionsUnited States
Clinical Trials on Gemcitabine
-
AstraZenecaRecruitingBiliary Tract CancerFrance, Spain, Italy, Korea, Republic of, Japan, Germany, United States, Singapore
-
Sierra Oncology LLC - a GSK companyCompletedAdvanced Solid TumorsSpain, United Kingdom
-
University of Erlangen-Nürnberg Medical SchoolCompleted
-
Shenzhen University General HospitalNot yet recruiting
-
3D Medicines (Sichuan) Co., Ltd.Not yet recruitingBiliary Tract Neoplasms
-
Kansai Hepatobiliary Oncology GroupCompleted
-
Fifth Affiliated Hospital, Sun Yat-Sen UniversityRecruiting
-
3D Medicines (Sichuan) Co., Ltd.RecruitingBiliary Tract NeoplasmsChina
-
Yung NAQueen Mary Hospital, Hong Kong; Pamela Youde Nethersole Eastern HospitalRecruitingMuscle-Invasive Bladder Carcinoma | Muscle Invasive Bladder Urothelial CarcinomaHong Kong
-
Air Force Military Medical University, ChinaRecruiting